Adaptin Bio (APTN) Net Cash Flow (2024 - 2026)

Adaptin Bio has disclosed Net Cash Flow across 3 years of filings, most recently posting -$157865.0 for Q1 2026.

• Quarterly Net Cash Flow fell 106.75% year-over-year to -$157865.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 187.5% YoY) and the FY2025 annual result came in at $425089.0, up 1349.28% from the prior year.
• Net Cash Flow fell to -$157865.0 in Q1 2026, from -$119915.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $2.3 million in Q1 2025 and bottomed at -$1.0 million in Q2 2025.
• The 3-year median for Net Cash Flow is -$81223.0 (2024), against an average of $32950.6.
• The widest YoY moves for Net Cash Flow: up 767160.33% in 2025, down 5564.07% in 2025.
• Adaptin Bio's Net Cash Flow stood at -$81223.0 in 2024, then sank by 47.64% to -$119915.0 in 2025, then slumped by 31.65% to -$157865.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$157865.0, -$119915.0, and -$772430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.